 AUSTIN, Texas, Nov. 05, 2020 GLOBE NEWSWIRE -- Molecular Templates, Inc. Nasdaq: MTEM, Molecular Templates, MTEM or the Company, a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies ETBs, today reported financial results for the third quarter of 2020 and an update on its clinical pipeline. 